Drug intelligence / Profile preview

tolonidine

Development stage: Discontinued
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

Tolonidine is an antihypertensive drug that belongs to the class of centrally acting alpha-2 adrenergic agonists, structurally related to clonidine. It acts by stimulating presynaptic alpha-2 adrenergic receptors in the central nervous system, leading to decreased sympathetic outflow and reduced blood pressure. Tolonidine was developed as an alternative to clonidine for the treatment of hypertension but is not widely used or marketed in most countries. Its mechanism of action involves reducing norepinephrine release from sympathetic nerve terminals, resulting in vasodilation and lowered heart rate.

Targets

ADRA2A (α2A)

Beyond the preview

Go deeper on tolonidine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tolonidine.

Explore the full profile